Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1508)	10/1/2015 9:02:18 AM
From: eico20	Read Replies (1) \| Respond to of 2026

from the AUG. 10Q - issue based on the sample in UK, older news, but why is Germany on hold, 10Q - "In July 2015, Sandoz reported that it was out of stock of Vitaros® in Germany. Sandoz has put a hold on releasing additional batches pending the results of an ongoing out-of-specification investigation by the Company’s contract manufacturer. Such investigation relates to a stability sample of Vitaros® manufactured for sale in the U.K. All relevant health authorities have been informed and are privy to the ongoing investigation. Sandoz continues to sell product in Sweden and Belgium and the Company’s other Vitaros®partners continue to release batches and sell product in the U.K., France and Spain."

To: phoenix_rising who wrote (1508)

10/1/2015 12:16:01 PM

From: Mirror Image

Read Replies (3) | Respond to of 2026

We are now in the next quarter and no update on how they plan to finance the coming year. This deal only covers the cost of the Allergan deal and a bit of change, so I don't expect much of any impact on PPS.

You are correct in the sense that this deal - as you point out - only covers the Allergan deal and a bit more. And more importantly, it does not completely answer next year's expenses ( especially with more trials on Fispemifene and the work that has to be done with Vitaros in the USA ).

What it allows to do in the short term is compare this deal versus the one that Apricus just signed with Allergan for the rights to the USA. The USA has a target market that is more or less 50% of the worldwide market. They regained U.S. rights for 1 M upfront and 1.5 M in a regulatory milestone. This deal for Latin America rights to Vitaros - nets Apricus $2.5 M upfront and another $16 M regulatory and sales milestones.

What is the percentage of the target market that Latin America represents out of the Worldwide picture?

In my opinion, it's a great deal for Apricus. Especially that it's done after the Allergan deal.

The one poster on IHUB has repeatedly said that Allegan did us ( Apricus ) a favor for allowing the $25 M buyback clause and that it was a P.R. move and nothing else ( he changes his views from MEGA Bull to MEGA Bear - depending on his current holdings - in my opinion ). And that we were dreaming if we thought that we would get $25 M for the rights to Vitaros in the U.S.

How does today's deal fit into that assertion? Must feel like a SLAP in the face! I must correct that, "it should feel like a slap in the face", but some people just don't have any shame.